viewVerona Pharma

Verona Pharma phase II drug delivered “statistically significant and clinically meaningful” increases in lung function

The trial of 40 moderate to severe chronic obstructive pulmonary disease patients assessed ensifentrine’s potential when delivered via pressurised metered-dose inhalers similar to the ones used by asthmatics

Verona Pharma -

Verona Pharma PLC (LON:VRP) (NASDAQ:VRNA) said it has delivered positive efficacy and safety data from a phase II trial of its drug for chronic obstructive pulmonary disease.

The study 40 moderate to severe COPD patients assessed ensifentrine’s potential when administered using pressurised metered-dose inhalers similar to the ones used by asthmatics.

It found the treatment delivered “statistically significant and clinically meaningful” increases in lung function across a range of doses.

The results, which also underscored the safety of the Verona discovery, chime with those from earlier trials of ensifentrine using nebulisers and dry powder inhalers as the delivery mechanism.

In a statement, Verona chief executive, David Zaccardelli, said the data from all three formulations supported twice-daily use of the drug.

However, in what is becoming a common theme in medical research, Verona has been forced to postpone enrollment to Part B of the firm’s pressurised metered-dose inhaler ensifentrine because of the coronavirus (COVID-19) outbreak.

The company’s end-of-phase II meeting with the US Food & Drug Administration is scheduled for the second quarter, while the start of phase III trials of the nebulised COPD treatment is planned for later this year.

To provide a sense of the scale of the opportunity being chased by Verona, an estimated 5.5mln people in the US alone use metered dose and dry powder inhalers to control the symptoms of COPD, a disease characterised by long-term breathing problems and poor airflow. Sales of these maintenance medications stateside were US$9bn last year.

For more details on the phase II study click here

Quick facts: Verona Pharma

Price: 40 GBX

Market: AIM
Market Cap: £42.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Verona Pharma named herein, including the promotion by the Company of Verona Pharma in any Content on the Site, the Company receives from said...



Morning Report: Smiths Group halts planned demerger of medical arm

Headlines from the Proactive UK newsroom. Smiths Group (LON:SMIN) has halted the planned demerger of its medical arm due to the coronavirus crisis. Smiths Medical needs to concentrate on the delivery of ventilators and other critical care devices, though the intention remains to separate once...

on 31/3/20

2 min read